1. Home
  2. BLRX

BLRX

BioLineRx Ltd.

Logo BioLineRx Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 11:26am EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Founded: 2003 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 57.3M IPO Year: 2011
Target Price: $12.50 AVG Volume (30 days): 429.2K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.06 EPS Growth: N/A
52 Week Low/High: $0.65 - $2.53 Next Earning Date: 05-22-2024
Revenue: $4,800,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: